Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Free Report

White Paper_2017_State of China Life Science

State of China Life Science - 2017H1

Over $10B invested in last 18 months! Download free report on life science investment in China.

IPO/Stock Watch

Market trends, bell-weather stocks, filings and IPOs...

Suzhou's Innovent Plans Capital Raise Followed by $200 Million IPO
Sisram Medical, Majority-Owned by Fosun, Stages $125 Million Hong Kong IPO
Zai Labs Completes $150 Million IPO; Stock Jumps 50% at Opening; Company Worth $1.4 Billion
Sisram, a Fosun Pharma Device Company, Staging a $200 Million Hong Kong IPO
Berry Genomics Completes $648 Million Reverse Merger in Shenzhen
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China